Sanara MedTech says FTC issued Second Request on MiMedx merger
On October 15, 2026, Sanara MedTech and MiMedx each received a Second Request from the Federal Trade Commission as part of its review of the proposed merger in which Sanara would become a wholly-owned subsidiary of MiMedx. Under the Hart-Scott-Rodino Act, the Second Request extends the waiting period until 30 days after the parties substantially comply, so closing is likely to take longer, and completion still depends on regulatory and other conditions.
Key points
- FTC issued a Second Request to Sanara and MiMedx on October 15, 2026.
- The Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended or terminated earlier.
- Completion remains subject to HSR waiting period expiration and other closing conditions in the Merger Agreement.
- The filing does not state a expected closing date or any financial figures for the deal.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.